Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 6/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.46 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.44 |
| ▸ | KCNK10 | P57789 | 1/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4833312 | 1.00 | PLK1 (0.52) | PLK1ALDH1A1NR1H4PPARGPPARD | |
| SCHEMBL4833858 | 0.95 | PLK1 (0.47) | PLK1ALDH1A1NR1H4PPARGPPARD | |
| SCHEMBL4833874 | 0.95 | PLK1 (0.47) | PLK1ALDH1A1NR1H4PPARGPPARD | |
| SCHEMBL4828963 | 0.93 | PLK1 (0.46) | PLK1ALDH1A1NR1H4PPARGPPARD | |
| SCHEMBL4828977 | 0.93 | PLK1 (0.46) | PLK1ALDH1A1NR1H4PPARGPPARD | |
| SCHEMBL4828804 | 0.92 | PLK1 (0.44) | PLK1ALDH1A1NR1H4PPARGPPARD | |
| SCHEMBL4828800 | 0.92 | PLK1 (0.44) | PLK1ALDH1A1NR1H4PPARGPPARD | |
| SCHEMBL4826497 | 0.91 | CTDSP1 (0.50) | PLK1ALDH1A1NR1H4PPARGPPARD | |
| SCHEMBL4826504 | 0.91 | CTDSP1 (0.50) | PLK1ALDH1A1NR1H4PPARGPPARD | |
| SCHEMBL5693729 | 0.88 | PLK1 (0.48) | PLK1ALDH1A1NR1H4PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7420083-B2 | Substituted aryloximes | WYETH (US) | 2008-09-02 | — | — | US | claimed |
| EP-1663189-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | claimed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | claimed |
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
| US-7420083-B2 | Substituted aryloximes | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| EP-1663189-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY)-PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIREMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBISIS | Wyeth (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005030193-A1 | 4-(PHENYL-ETHYLIDENEAMINOXY-PROPOXY) -PHENYL-ACETIC ACID DERIVATIVES AND RELATED COMPOUNDS AS PAI-1 INHIBITORS FOR THE TREATMENT OF IMPAIRMENT OF THE FIBRINOLYTIC SYSTEM AND OF THROMBOSIS | WYETH (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070584-A1 | Substituted aryloximes | WYETH (US) | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070584-A1 | Substituted aryloximes | AHR, NQO1, AOX1 | PLK1 3639/4885ALDH1A1 269/4885NR1H4 1826/4885 |
| US-20080293790-A1 | SUBSTITUTED ARYL OXIMES | HCCS, AOX1, TET2 | PLK1 4185/4885ALDH1A1 211/4885NR1H4 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.